73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Harmony Biosciences Holdings Inc
Closed
SectorHealthcare
37.67 3.26
Overview
Share price change
24h
Min
35.94
Max
38.02
Income | 11M 51M |
|---|---|
Sales | 39M 239M |
P/E Sector Avg | 11.786 90.422 |
EPS | 1.08 |
Profit margin | 21.242 |
Employees | 268 |
EBITDA | 14M 73M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +19.8% upside |
Next Earnings | 24 Feb 2026 |
|---|
Market Cap | 464M 2.2B |
|---|---|
Previous open | 34.41 |
Previous close | 37.67 |
News Sentiment
By Acuity
40%
60%
92 / 352 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Harmony Biosciences Holdings Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Harmony Biosciences Holdings Inc Forecast
Price Target
By TipRanks
19.8% upside
12 Months Forecast
Average 43.75 USD 19.8%
High 55 USD
Low 32 USD
Based on 5 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.
Sentiment
By Acuity
92 / 352 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Live chat